Supplier News: Actylis, Resilience, Asahi Kasei & More
The latest from CDMOs, CMOs, and suppliers featuring Actylis, National Resilience, Asahi Kasei, Bend Bioscience, 3P Biopharmaceuticals and PackGene Biotech
Chemicals/Chemical API Manufacturing
* Actylis Opens New API & Excipient Mfg Facility
Biologics Manufacturing
* National Resilience To Sell, Lease Back Massachusetts Biomanufacturing Facility
* 3P Bio Increases Microbial Production Capacity
* PackGene Biotech Breaks Ground on Gene-Therapy Mfg Facility
Formulation Development/Drug Product Manufacturing
* Bend Bioscience Opens R&D & Innovation Lab
* Asahi Kasei Completes Construction of Excipient Mfg Facility
Chemicals/Chemical API Manufacturing
Actylis Opens New API & Excipient Mfg Facility
Actylis (formerly Aceto), a manufacturer and distributor, has opened a new 30,000-square-foot cGMP manufacturing facility for active pharmaceutical ingredients and excipients in Eugene, Oregon. The facility provides manufacturing on both clinical and commercial scales.
The Eugene facility is the latest GMP manufacturing facility that Actylis has commissioned—along with the other GMP sites in Montreal, Canada; Limerick, Ireland; and Ahmedabad, India.
Source: Actylis
Biologics Manufacturing
National Resilience To Sell, Lease Back Massachusetts Biomanufacturing Facility
National Resilience, a CDMO of biologics and advanced therapies, has agreed to sell its 120,000-square foot biomanufacturing facility in Marlborough, Massachusetts, to Oxford Properties Group, a real estate investor and asset manager. Oxford will acquire the facility, which is under construction and nearing completion, and lease the property back to Resilience for up to 30 years. This deal structure raises proceeds for Resilience while allowing it to conduct its day-to-day business operations with full use of the facility. The deal is expected to close later this year (2023).
Source: Oxford Properties Group
3P Bio Increases Microbial Production Capacity
3P Biopharmaceuticals (3P), a Pamplona, Navarre, Spain-based CDMO of biologics, has installed a new 500-L stainless-steel fermenter to increase its existing capacity for protein production from bacteria and yeast.
The new capacity adds to three existing fermentation lines that carry out drug production from bacteria and yeast. The company now has capacities for microbial manufacturing of 10 L, 100 L, 500 L and 1,000 L. With the expansions carried out over the last three years, its facilities now total 10,500 m2.
Source: 3P Biopharmaceuticals
PackGene Biotech Breaks Ground on Gene-Therapy Mfg Facility
PackGene Biotech, a CRO and CDMO of adeno-associated-viral-vector gene therapies, has broken ground for a new 25,000-square-foot cGMP biomanufacturing and processing facility in Houston, Texas. The facility will include process and analytical laboratories, cGMP manufacturing cleanrooms and support areas, quality control laboratories, a warehouse, and office space. The company plans to nearly triple its Houston-area workforce to about 60 by the end of 2023 when the new facility is expected to be completed. Founded in Massachusetts, PackGene has additional operations in China (Guangzhou and Shanghai) and Boston.
Source: PackGene Biotech
Formulation Development/Drug Product Manufacturing
Bend Bioscience Opens R&D & Innovation Lab
Bend Bioscience, a Bend, Oregon-based CDMO of drug products, has opened an R&D and Innovation Lab in Bend, Oregon. The new lab has 4,500 square feet of lab and office space and a work environment for approximately 20 employees. The facility is part of a larger planned footprint that includes process science and clinical manufacturing facilities planned to open later this year (2023). Bend Bioscience focuses on early-phase manufacturing for formulations using particle engineering-based drug-delivery technologies.
Source: Bend Bioscience
Asahi Kasei Completes Construction of Excipient Mfg Facility
Asahi Kasei has completed the construction of its second plant for its Ceolus microcrystalline cellulose (MCC), an excipient, at its Mizushima Works site in Kurashiki, Okayama, Japan. Asahi Kasei has manufactured Ceolus in Nobeoka, Miyazaki, Japan, since 1970. It is primarily used as a tablet binder for pharmaceuticals. The new JPY 13-billion ($96-million) plant is currently undergoing trial operation, with commercial production of each grade scheduled to begin in succession from April 2023.
Source: Asahi Kasei
